A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I

被引:15
作者
Traino, AC
Di Martino, F
Grosso, M
Monzani, F
Dardano, A
Caraccio, N
Mariani, G
Lazzeri, M
机构
[1] Azienda Osped Univ Pisana, Sez Fis Med, UO Fis Sanitaria, I-56125 Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Fis Sanitaria, I-56125 Pisa, Italy
[3] Azienda Osped Univ Pisana, Ctr Reg Med Nucl, I-56125 Pisa, Italy
[4] Univ Pisa, Dipartimento Med Interna, I-56125 Pisa, Italy
关键词
D O I
10.1088/0031-9155/50/9/018
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Substantial reductions in thyroid volume (up to 70-80%) after radioiodine therapy of Graves' hyperthyroidism are common and have been reported in the literature. A relationship between thyroid volume reduction and outcome of I-131 therapy of Graves' disease has been reported by some authors. This important result could be used to decide individually the optimal radioiodine activity A(0) (MBq) to administer to the patient, but a predictive model relating the change in gland volume to A(0) is required. Recently, a mathematical model of thyroid mass reduction during the clearance phase (30-35 days) after I-131 administration to patients with Graves' disease has been published and used as the basis for prescribing the therapeutic thyroid absorbed dose. It is well known that the thyroid volume reduction goes on until 1 year after therapy. In this paper, a mathematical model to predict the final mass of Graves' diseased thyroids submitted to I-131 therapy is presented. This model represents a tentative explanation of what occurs macroscopically after the end of the clearance phase of radioiodine in the gland (the so-called second-order effects). It is shown that the final thyroid mass depends on its basal mass, on the radiation dose absorbed by the gland and on a constant value a typical of thyroid tissue. a has been evaluated based on a set of measurements made in 15 reference patients affected by Graves' disease and submitted to I-131 therapy. A predictive equation for the calculation of the final mass of thyroid is presented. It is based on macroscopic parameters measurable after a diagnostic I-131 capsule administration (0.37-1.85 MBq), before giving the therapy. The final mass calculated using this equation is compared to the final mass of thyroid measured 1 year after therapy administration in 22 Graves' diseased patients. The final masses calculated and measured 1 year after therapy are in fairly good agreement (R = 0.81). The possibility, for the physician, to decide a therapeutic activity based on the desired decrease of thyroid mass instead of on a fixed thyroid absorbed dose could be a new opportunity to cure Graves' disease.
引用
收藏
页码:2181 / 2191
页数:11
相关论文
共 20 条
  • [1] Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: Is more than seven-thousand rad target dose necessary?
    Bajnok, L
    Mezosi, E
    Nagy, E
    Szabo, J
    Sztojka, I
    Varga, J
    Galuska, L
    Leovey, A
    [J]. THYROID, 1999, 9 (09) : 865 - 869
  • [2] Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome
    Catargi, B
    Leprat, F
    Guyot, M
    Valli, N
    Ducassou, D
    Tabarin, A
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 141 (02) : 117 - 121
  • [3] Outcome of thyroid function in Graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage
    Chiovato, L
    Fiore, E
    Vitti, P
    Rocchi, R
    Rago, T
    Dokic, D
    Latrofa, F
    Mammoli, C
    Lippi, F
    Ceccarelli, C
    Pinchera, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) : 40 - 46
  • [4] A theoretical model for prescription of the patient-specific therapeutic activity therapy of Graves' disease
    Di Martino, F
    Traino, AC
    Brill, AB
    Stabin, MG
    Lazzeri, M
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2002, 47 (09) : 1493 - 1499
  • [5] Gómez-Arnaiz N, 2003, HORM METAB RES, V35, P492
  • [6] Radioiodine therapy in Graves' hyperthyroidism:: Determination of individual optimum target dose
    Haase, A
    Bähre, M
    Lauer, I
    Meller, B
    Richter, E
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (02) : 133 - 137
  • [7] Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study
    Howarth, D
    Epstein, M
    Lan, L
    Tan, P
    Booker, J
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (10) : 1489 - 1495
  • [8] IS CALCULATION OF THE DOSE IN RADIOIODINE THERAPY OF HYPERTHYROIDISM WORTH WHILE
    JARLOV, AE
    HEGEDUS, L
    KRISTENSEN, LO
    NYGAARD, B
    HANSEN, JM
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 43 (03) : 325 - 329
  • [9] Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism
    Jönsson, H
    Mattssoni, S
    [J]. RADIATION PROTECTION DOSIMETRY, 2004, 108 (02) : 107 - 114
  • [10] Changes in thyroid volume in response to radioactive iodine for Graves hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome
    Murakami, Y
    Takamatsu, J
    Sakane, S
    Kuma, K
    Ohsawa, N
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) : 3257 - 3260